Initial clinical experience with ribociclib in advanced HR+/HER2− breast cancer in Uruguay
Main Article Content
Keywords
Breast Neoplasms, Ribociclib , Therapy, Hormone Replacement, Retrospective Studies
Abstract
Abstract
Background: Ribociclib improves progression-free and overall survival (PFS and OS) in women with advanced HR+/HER2− breast cancer (BC), but real-world evidence in Uruguay is limited.
Objective: To describe the clinical characteristics, outcomes, and safety profile of women with advanced HR+/HER2− breast cancer treated with ribociclib plus hormone therapy in Uruguay.
Materials and methods: Observational, retrospective study. Demographic and clinical variables, type of hormone therapy, treatment duration, and adverse events were analyzed.
Results: A total of 54 patients from public and private institutions were included, with a median age of 60 years. 67% relapsed after adjuvant treatment. Bone was the most common metastatic site (72%). Ribociclib was administered as first-line treatment in 81% of cases, and combined with aromatase inhibitors in 63%. The mean OS was 41.6 months and the mean PFS was 30 months; medians were not reached. Neutropenia was the most frequent adverse event (66%), followed by gastrointestinal toxicity (nausea 33%, diarrhea 28%) and skin toxicity (16%). One death due to pulmonary embolism was recorded, and QTc prolongation was documented in 5.6% of patients. Dose reduction was required in 20%, and one patient discontinued treatment due to skin toxicity.
Conclusion: Ribociclib was well tolerated, with a safety profile consistent with the literature. This study provides relevant local evidence and supports its use in real-world settings. Longer follow-up is needed to more accurately assess OS and PFS outcomes.
References
1. Garau M, Musetti C, Alonso R, et al. Estadio, perfil biológico y tendencias de incidencia y mortalidad de cáncer de mama en Uruguay: Análisis por franjas etarias. Rev. Méd. Urug. 2024;40(1):e203. doi: 10.29193/RMU.40.1.3
2. Lawton TJ. Update on the Use of Molecular Subtyping in Breast Cancer. Adv Anat Pathol. 2023;30(6):368-73. doi: 10.1097/PAP.0000000000000416
3. Pautas de Oncología Médica para el diagnóstico, tratamiento sistémico y seguimiento del cáncer de mama avanzado. Montevideo, Uruguay: Servicio de Oncología Médica. Disponible en: https://oncologiamedica.hc.edu.uy/publicaciones/pautas-de-oncologia-medica-para-el-diagnostico-tratamiento-sistemico-y-seguimiento/
4. Cardoso F, Paluch-Shimon S, Schumacher-Wulf E, et al. 6th and 7th International consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7). Breast. 2024;76:103756. doi: 10.1016/j.breast.2024.103756
5. Valencia F, Gómez HL, Neciosup SP, et al. Advanced Breast Cancer Guidelines in Latin America: Assessment, Adaptation, and Implementation of Fifth Advanced Breast Cancer Consensus Guidelines. JCO Glob Oncol. 2024 Feb;10:e2200067. doi: 10.1200/GO.22.00067
6. Hortobagyi GN, Stemmer SM, Burris HA, et al. Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer. N Engl J Med. 2022;386(10):942-50. doi: 10.1056/NEJMoa2114663
7. Lu YS, Im SA, Colleoni M, et al. Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2- Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial. Clin Cancer Res. 2022;28(5):851-859. doi: 10.1158/1078-0432.CCR-21-3032
8. Slamon DJ, Neven P, Chia S, et al. Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer. N Engl J Med. 2020;382(6):514-24. doi: 10.1056/NEJMoa1911149
9. Mubarak F, Kowkabany G, Popp R, et al. Early Stage Breast Cancer: Does Histologic Subtype (Ductal vs. Lobular) Impact 5 Year Overall Survival? Cancers (Basel). 2024;16(8):1509. doi: 10.3390/cancers16081509
10. Castillo C, Camejo N, Amarillo D, et al. Impact of the COVID-19 pandemic on health care activities at a Uruguayan mastology unit. J Cancer Res Ther. 2021;17(2):547-50. doi: 10.4103/jcrt.JCRT_1689_20
11. PDQ Adult Treatment Editorial Board. Breast Cancer Treatment (PDQ®): Health Professional Version. 2025 Mar 14. In: PDQ Cancer Information Summaries. Bethesda (MD): National Cancer Institute (US); 2002–. Disponible en: https://pubmed.ncbi.nlm.nih.gov/26389187/
12. Cardoso F, Kyriakides S, Ohno S, et al. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Ann Oncol. 2019;30(8):1194-220. doi: 10.1093/annonc/mdz173. Erratum in: Ann Oncol. 2019 Oct 1;30(10):1674. doi: 10.1093/annonc/mdz189. Erratum in: Ann Oncol. 2021 Feb;32(2):284. doi: 10.1016/j.annonc.2020.08.2158
13. Lee YJ, Jung SP, Bae JW, et al. Prognosis according to the timing of recurrence in breast cancer. Ann Surg Treat Res. 2023;104(1):1-9. doi: 10.4174/astr.2023.104.1.1
14. Torrisi R, Jacobs F, Miggiano C, et al. HR+/HER2- de novo metastatic breast cancer: a true peculiar entity? Drugs Context. 2023;12:2022-12-2. doi: 10.7573/dic.2022-12-2
15. File DM, Pascual T, Deal AM, et al. Clinical subtype, treatment response, and survival in De Novo and recurrent metastatic breast cancer. Breast Cancer Res Treat. 2022;196(1):153-62. doi: 10.1007/s10549-022-06700-6
16. Nawaz A, Zekri J, Rasool H, et al. Initial real-world experience with ribociclib in advanced breast cancer. J Oncol Pharm Pract. 2025:10781552251317962. doi: 10.1177/10781552251317962
17. Suzuki DA, Morelle AM, de Brito ML, et al. Real-World Evidence of Ribociclib Plus Aromatase Inhibitors as First-Line Treatment in Advanced Breast Cancer: The BrasiLEEira Study. JCO Glob Oncol. 2024;10:e2300484. doi: 10.1200/GO.23.00484
18. Hart LL, Im SA, Tolaney SM, et al. Efficacy, safety, and patient-reported outcomes across young to older age groups of patients with HR+/HER2- advanced breast cancer treated with ribociclib plus endocrine therapy in the randomized MONALEESA-2, -3, and -7 trials. Eur J Cancer. 2025;217:115225. doi:10.1016/j.ejca.2025.115225
19. Trigueros D, Landaverde D. Real-world data on the effectiveness and toxicity of CDK 4/6 inhibitors combined with hormonal therapy in patients with metastatic hormone receptor-positive and HER2-negative breast cancer in first- and second-line treatments within the Costa Rican health care system. Journal of Clinical Oncology. 2025;43(Suppl 16):e13053. doi: 10.1200/JCO.2025.43.16_suppl.e13053
20. Sanò MV, Martorana F, Lavenia G, et al. Ribociclib efficacy in special populations and analysis of patient-reported outcomes in the MONALEESA trials. Expert Rev Anticancer Ther. 2022;22(4):343-51. doi: 10.1080/14737140.2022.2052277
21. Wong V, de Boer R, Baron-Hay S, et al. Real-World Outcomes of Ribociclib and Aromatase Inhibitor Use in First Line Hormone Receptor Positive, HER2-Negative Metastatic Breast Cancer. Clin Breast Cancer. 2022;22(8):792-800. doi: 10.1016/j.clbc.2022.08.011
22. Chen BF, Tsai YF, Chao TC, et al. Real-world experience with CDK4/6 inhibitors in hormone receptor-positive metastatic and recurrent breast cancer: findings from an Asian population. Clin Exp Med. 2024;24(1):185. doi: 10.1007/s10238-024-01458-1
23. O'Sullivan CC, Clarke R, Goetz MP, et al. Cyclin-Dependent Kinase 4/6 Inhibitors for Treatment of Hormone Receptor-Positive, ERBB2-Negative Breast Cancer: A Review. JAMA Oncol. 2023;9(9):1273-82. doi: 10.1001/jamaoncol.2023.2000
24. U.S. Food and Drug Administration (FDA). FDA Adverse Event Reporting System (FAERS) Public Dashboard. Silver Spring (MD): FDA. Disponible en: https://fis.fda.gov/sense/app/777e9f4e-0cf8-448e-abda-63f06d57c6c3
25. Gao S, Li Y, He Z, et al. Thromboembolism profiles associated with cyclin-dependent kinase 4/6 inhibitors: a real-world pharmacovigilance study and a systematic review. Expert Opin Drug Saf. 2023;22(7):599-609. doi: 10.1080/14740338.2023.2181338
Article Sidebar
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Authors retain their copyright and grant the Revista Médica del IMSS the right of first publication. Articles are distributed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which allows sharing as long as the author and the original source are properly credited.